FDA approves Kite’s gene therapy for mantle cell lymphoma July 24, 2020 By Lee Landenberger No Comments The FDA approved Kite Pharma Inc.’s Tecartus (brexucabtagene autoleucel, KTE-X19), the first cell-based gene therapy for adults with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment.Read More